Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 18, 2023

Circulating Pretreatment T-Cell Receptor Repertoire as a Predictive Biomarker in Patients With Advanced or Metastatic NSCLC Treated With Pembrolizumab ± Chemotherapy



Additional Info

Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy
ESMO Open 2023 Nov 22;8(6)102066, A Abed, AB Beasley, AL Reid, N Law, L Calapre, M Millward, J Lo, ES Gray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading